IFF (IFF) Sells Pharma Solutions Business to Roquette for Up to $2.85B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
International Flavors & Fragrances (IFF) PT Raised to $85 at BofA Securities
March 20, 2024 2:10 PM EDTBofA Securities analyst Matthew DeYoe raised the price target on International Flavors & Fragrances (NYSE: IFF) to $85.00 (from $83.00) while maintaining a Neutral rating.
The analyst comments "Yesterday, IFF announced an agreement to sell its Pharma Solutions business to Roquette for $2.85bn. The transaction reflects a... More
International Flavors & Fragrances (IFF) PT Raised to $100 at Deutsche Bank
March 20, 2024 5:19 AM EDTDeutsche Bank analyst David Begleiter raised the price target on International Flavors & Fragrances (NYSE: IFF) to $100.00 (from $90.00) while maintaining a Buy rating.
The analyst comments "With the sale of Pharma Solutions, IFF has taken a major step in reducing its leverage below 3x and thus removing the leverage overhang on the shares that has existed since the... More
International Flavors & Fragrances (IFF) PT Raised to $85 at Stifel
March 19, 2024 10:24 AM EDTStifel analyst Mark Astachan raised the price target on International Flavors & Fragrances (NYSE: IFF) to $85.00 (from $80.00) while maintaining a Hold rating after selling its Pharma business for up to $2.85 billion.
The analyst commented, "IFF announced the sale of its Pharma business for up to $2.85bn,... More

